Nexvet Biopharma Stock Price, News & Analysis (NASDAQ:NVET)

$6.72 0.00 (0.00 %)
(As of 02/20/2018 04:23 AM ET)
Previous Close$6.72
Today's Range$6.69 - $6.72
52-Week Range$2.75 - $6.76
Volume33,400 shs
Average Volume38,104 shs
Market Capitalization$81.61 million
P/E Ratio-3.84
Dividend YieldN/A
BetaN/A

About Nexvet Biopharma (NASDAQ:NVET)

Nexvet Biopharma logoNexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company's platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal's immune system, a property referred to as 100% species-specificity. PETization is designed to build upon the safety and efficacy data from clinically tested human therapies to create new therapies for companion animals. Biologics generally include mAbs, which are targeted antibodies derived from identical (clonal) cells. The Company's advanced product candidates are in pivotal-phase development: ranevetmab (or NV-01) and frunevetmab (or NV-02).

Receive NVET News and Ratings via Email

Sign-up to receive the latest news and ratings for NVET and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:NVET
CUSIPN/A
Phone+353-1-2158100

Debt

Debt-to-Equity RatioN/A
Current Ratio5.34%
Quick Ratio5.34%

Price-To-Earnings

Trailing P/E Ratio-3.84
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($1.75)
Net IncomeN/A
Net MarginsN/A
Return on Equity-102.72%
Return on Assets-89.82%

Miscellaneous

Employees51
Outstanding Shares11,920,000

Nexvet Biopharma (NASDAQ:NVET) Frequently Asked Questions

What is Nexvet Biopharma's stock symbol?

Nexvet Biopharma trades on the NASDAQ under the ticker symbol "NVET."

How were Nexvet Biopharma's earnings last quarter?

Nexvet Biopharma plc (NASDAQ:NVET) announced its earnings results on Thursday, May, 11th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.02. View Nexvet Biopharma's Earnings History.

Where is Nexvet Biopharma's stock going? Where will Nexvet Biopharma's stock price be in 2018?

1 brokerages have issued 1 year target prices for Nexvet Biopharma's shares. Their predictions range from $6.72 to $6.72. On average, they anticipate Nexvet Biopharma's stock price to reach $6.72 in the next year. View Analyst Ratings for Nexvet Biopharma.

Who are some of Nexvet Biopharma's key competitors?

When did Nexvet Biopharma IPO?

(NVET) raised $58 million in an initial public offering on Thursday, February 5th 2015. The company issued 4,000,000 shares at a price of $13.00-$16.00 per share. BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Piper Jaffray and JMP Securities were co-managers.

How do I buy Nexvet Biopharma stock?

Shares of Nexvet Biopharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nexvet Biopharma's stock price today?

One share of Nexvet Biopharma stock can currently be purchased for approximately $6.72.

How big of a company is Nexvet Biopharma?

Nexvet Biopharma has a market capitalization of $81.61 million. Nexvet Biopharma employs 51 workers across the globe.

How can I contact Nexvet Biopharma?

Nexvet Biopharma's mailing address is Unit 5 Sragh Technology Park, Rahan Road, TULLAMORE, R35 FR98, Ireland. The biopharmaceutical company can be reached via phone at +353-1-2158100.


MarketBeat Community Rating for Nexvet Biopharma (NVET)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about Nexvet Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Nexvet Biopharma (NASDAQ:NVET) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.72$6.72$6.72$6.72
Price Target Upside: 1.82% upside1.82% upside1.82% upside1.82% upside

Nexvet Biopharma (NASDAQ:NVET) Consensus Price Target History

Price Target History for Nexvet Biopharma (NASDAQ:NVET)

Nexvet Biopharma (NASDAQ:NVET) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/24/2017Credit Suisse GroupDowngradeOutperform -> Neutral$8.00 -> $6.72LowView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Nexvet Biopharma (NASDAQ:NVET) Earnings History and Estimates Chart

Earnings by Quarter for Nexvet Biopharma (NASDAQ:NVET)

Nexvet Biopharma (NASDAQ NVET) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/20173/31/2017($0.49)($0.51)ViewN/AView Earnings Details
2/10/201712/31/2016($0.37)($0.46)ViewN/AView Earnings Details
11/4/2016Q1($0.41)($0.44)ViewN/AView Earnings Details
9/2/2016Q4 2016($0.48)($0.34)ViewN/AView Earnings Details
5/12/2016Q3($0.44)($0.50)ViewN/AView Earnings Details
2/16/2016Q2 2016($0.48)($0.49)ViewN/AView Earnings Details
11/5/2015Q1 2016($0.51)($0.35)ViewN/AView Earnings Details
9/3/2015Q4 2015($0.35)($0.39)ViewN/AView Earnings Details
5/8/2015Q115($0.20)($0.36)ViewN/AView Earnings Details
3/13/2015Q2 2015($0.55)($2.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Nexvet Biopharma (NASDAQ:NVET) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Nexvet Biopharma (NASDAQ:NVET)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Nexvet Biopharma (NASDAQ NVET) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 37.00%
Institutional Ownership Percentage: 48.38%
Insider Trades by Quarter for Nexvet Biopharma (NASDAQ:NVET)
Insider Trades by Quarter for Nexvet Biopharma (NASDAQ:NVET)

Nexvet Biopharma (NASDAQ NVET) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/4/2016David GearingInsiderBuy11,113$3.33$37,006.295,600View SEC Filing  
3/2/2016Ashraf HannaDirectorBuy1,500$3.20$4,800.005,820View SEC Filing  
2/26/2016Farallon Capital Management LlInsiderBuy435,000$3.19$1,387,650.00View SEC Filing  
2/24/2016Cormac G KiltyDirectorBuy3,000$3.17$9,510.003,600View SEC Filing  
9/10/2015Farallon Capital Management LlInsiderBuy11,100$6.46$71,706.00View SEC Filing  
9/9/2015Cormac G KiltyDirectorBuy10,000$4.79$47,900.003,600View SEC Filing  
2/10/2015One Funds Management Ltd Atf AMajor ShareholderBuy100,000$10.00$1,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Nexvet Biopharma (NASDAQ NVET) News Headlines

Source:
DateHeadline
Critical Comparison: Nexvet Biopharma (NVET) & Its RivalsCritical Comparison: Nexvet Biopharma (NVET) & Its Rivals
www.americanbankingnews.com - December 28 at 8:48 AM
Achaogen (AKAO) and Nexvet Biopharma (NVET) Critical SurveyAchaogen (AKAO) and Nexvet Biopharma (NVET) Critical Survey
www.americanbankingnews.com - December 20 at 9:32 AM
Contrasting Nexvet Biopharma (NVET) and The CompetitionContrasting Nexvet Biopharma (NVET) and The Competition
www.americanbankingnews.com - December 6 at 7:25 PM
Nexvet Biopharma plc (NVET) Set to Announce Quarterly Earnings on ThursdayNexvet Biopharma plc (NVET) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - August 24 at 1:15 AM
Nexvet Biopharma plc ("Nexvet") Rule 17(d) AnnouncementNexvet Biopharma plc ("Nexvet") Rule 17(d) Announcement
finance.yahoo.com - July 29 at 5:43 AM
Nexvet Biopharma plc ("Nexvet") Rule 17(c) AnnouncementNexvet Biopharma plc ("Nexvet") Rule 17(c) Announcement
finance.yahoo.com - July 11 at 6:05 AM
Nexvet Biopharma plc ("Nexvet") Supplement AnnouncementNexvet Biopharma plc ("Nexvet") Supplement Announcement
finance.yahoo.com - July 4 at 2:25 AM
Zoetis To Acquire Nexvet Biopharma For Animal Pain ManagementZoetis To Acquire Nexvet Biopharma For Animal Pain Management
seekingalpha.com - April 17 at 6:08 PM
Zoetis to Acquire Nexvet for US$6.72 in Cash Per ShareZoetis to Acquire Nexvet for US$6.72 in Cash Per Share
www.businesswire.com - April 13 at 6:41 PM
NEXVET BIOPHARMA PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and ExhibitsNEXVET BIOPHARMA PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - March 13 at 10:00 AM
Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017Nexvet Reports Financial Results for Second Quarter of Fiscal Year 2017
us.rd.yahoo.com - February 10 at 7:54 PM
Q2 2017 Nexvet Biopharma plc Earnings Release - Time Not SuppliedQ2 2017 Nexvet Biopharma plc Earnings Release - Time Not Supplied
biz.yahoo.com - February 10 at 7:54 PM
NEXVET BIOPHARMA PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, SubmissionNEXVET BIOPHARMA PLC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission
biz.yahoo.com - November 18 at 9:45 AM
NEXVET BIOPHARMA PLC Files SEC form 10-K, Annual ReportNEXVET BIOPHARMA PLC Files SEC form 10-K, Annual Report
biz.yahoo.com - September 2 at 11:21 AM
Q4 2016 Nexvet Biopharma plc Earnings Release - Time Not SuppliedQ4 2016 Nexvet Biopharma plc Earnings Release - Time Not Supplied
biz.yahoo.com - September 2 at 11:21 AM
NEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhiNEXVET BIOPHARMA PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi
biz.yahoo.com - September 2 at 11:21 AM

SEC Filings

Nexvet Biopharma (NASDAQ:NVET) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Nexvet Biopharma (NASDAQ:NVET) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Nexvet Biopharma (NASDAQ NVET) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.